Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy

Virology

Volumn 415, Issue 2, 2011, Pages 95-106

  Joshi, Anjali ^a   Garg, Himanshu ^a   Ablan, Sherimay ^b   Freed, Eric O ^b   Nagashima, Kunio ^c   Manjunath, N ^a   Shankar, Premlata ^a  

^a Paul L Foster School of Medicine   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Dominant negative; Envelope; Gag; Gene therapy; HIV; HIV entry; Virus assembly

Indexed keywords

CD34 ANTIGEN; LENTIVIRUS VECTOR;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENVELOPE GENE; GENE LOCATION; GENE THERAPY; GROUP SPECIFIC ANTIGEN GENE; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENE; VIRUS INHIBITION; VIRUS RELEASE; VIRUS REPLICATION;

CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; VIRUS ASSEMBLY; VIRUS INTERNALIZATION; VIRUS REPLICATION; VIRUS SHEDDING;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 79957693501     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.03.028     Document Type: Article

References (52)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
2. Bahner I., Sumiyoshi T., Kagoda M., Swartout R., Peterson D., Pepper K., Dorey F., Reiser J., Kohn D.B. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther. 2007, 15:76-85.
3. Blair W.S., Pickford C., Irving S.L., Brown D.G., Anderson M., Bazin R., Cao J., Ciaramella G., Isaacson J., Jackson L., Hunt R., Kjerrstrom A., Nieman J.A., Patick A.K., Perros M., Scott A.D., Whitby K., Wu H., Butler S.L. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010, 6:e1001220.
4. Buchschacher G.L., Freed E.O., Panganiban A.T. Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum. Gene Ther. 1992, 3:391-397.
5. Checkley M.A., Luttge B.G., Soheilian F., Nagashima K., Freed E.O. The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology 2010, 400:137-144.
6. Chukkapalli V., Hogue I.B., Boyko V., Hu W.S., Ono A. Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. J. Virol. 2008, 82:2405-2417.
7. Deeks S.G., McCune J.M. Can HIV be cured with stem cell therapy?. Nat. Biotechnol. 2010, 28:807-810.
8. Ding S., Lombardi R., Nazari R., Joshi S. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins. Front. Biosci. 2002, 7:a15-28.
9. Felber B.K., Hadzopoulou-Cladaras M., Cladaras C., Copeland T., Pavlakis G.N. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl Acad. Sci. USA 1989, 86:1495-1499.
10. Freed E.O. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998, 251:1-15.
11. Freed E.O., Delwart E.L., Buchschacher G.L., Panganiban A.T. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc. Natl Acad. Sci. USA 1992, 89:70-74.
12. Freed E.O., Englund G., Martin M.A. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J. Virol. 1995, 69:3949-3954.
13. Freed E.O., Martin M.A. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 1995, 270:23883-23886.
14. Freed E.O., Martin M.A. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J. Virol. 1995, 69:1984-1989.
15. Freed E.O., Martin M.A. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J. Virol. 1996, 70:341-351.
16. Freed E.O., Myers D.J., Risser R. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl Acad. Sci. USA 1990, 87:4650-4654.
17. Freed E.O., Orenstein J.M., Buckler-White A.J., Martin M.A. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J. Virol. 1994, 68:5311-5320.
18. Garg H., Blumenthal R. Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell. Mol. Life Sci. 2008, 65:3134-3144.
19. Garg H., Joshi A., Blumenthal R. Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants. AIDS Res. Hum. Retroviruses 2009, 25:811-817.
20. Garg H., Joshi A., Freed E.O., Blumenthal R. Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J. Biol. Chem. 2007, 282:16899-16906.
21. Gougeon M.L. Apoptosis as an HIV strategy to escape immune attack. Nat. Rev. Immunol. 2003, 3:392-404.
22. Hadzopoulou-Cladaras M., Felber B.K., Cladaras C., Athanassopoulos A., Tse A., Pavlakis G.N. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. Virol. 1989, 63:1265-1274.
23. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G.M., Kohn D.B., Gregory P.D., Holmes M.C., Cannon P.M. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 2010, 28:839-847.
24. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., Schneider T., Hofmann J., Kucherer C., Blau O., Blau I.W., Hofmann W.K., Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360:692-698.
25. Inubushi R., Shimano R., Oshima Y., Adachi A. The potential of various HIV-1 mutants to inhibit the replication of wild-type virus. Biochem. Biophys. Res. Commun. 1998, 247:349-352.
26. Iwatani Y., Kawano K., Ueno T., Tanaka M., Ishimoto A., Ito M., Sakai H. Analysis of dominant-negative effects of mutant Env proteins of human immunodeficiency virus type 1. Virology 2001, 286:45-53.
27. Joshi A., Nagashima K., Freed E.O. Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J. Virol. 2006, 80:7939-7951.
28. Kawada S., Goto T., Haraguchi H., Ono A., Morikawa Y. Dominant negative inhibition of human immunodeficiency virus particle production by the nonmyristoylated form of gag. J. Virol. 2008, 82:4384-4399.
29. Kohn D. Gene therapy using hematopoietic stem cells. Curr. Opin. Mol. Ther. 1999, 1:437-442.
30. Kohn D., Sarver N. Gene therapy for HIV-1 infection. Adv. Exp. Med. Biol. 1996, 394:421-428.
31. Lee S.K., Harris J., Swanstrom R. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 2009, 83:8536-8543.
32. Legiewicz M., Badorrek C.S., Turner K.B., Fabris D., Hamm T.E., Rekosh D., Hammarskjold M.L., Le Grice S.F. Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element. Proc. Natl Acad. Sci. USA 2008, 105:14365-14370.
33. Liu Y.P., Berkhout B. Lentiviral delivery of RNAi effectors against HIV-1. Curr. Top. Med. Chem. 2009, 9:1130-1143.
34. Mammano F., Ohagen A., Hoglund S., Gottlinger H.G. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 1994, 68:4927-4936.
35. Muller B., Anders M., Akiyama H., Welsch S., Glass B., Nikovics K., Clavel F., Tervo H.M., Keppler O.T., Krausslich H.G. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 2009, 284:29692-29703.
36. Murakami T., Freed E.O. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J. Virol. 2000, 74:3548-3554.
37. Murakami T., Freed E.O. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc. Natl Acad. Sci. USA 2000, 97:343-348.
38. Nazari R., Joshi S. CCR5 as target for HIV-1 gene therapy. Curr. Gene Ther. 2008, 8:264-272.
39. Perfettini J.L., Castedo M., Roumier T., Andreau K., Nardacci R., Piacentini M., Kroemer G. Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ. 2005, 12(Suppl 1):916-923.
40. Rossi J., June C., Kohn D. Genetic therapies against HIV. Nat. Biotechnol. 2007, 25:1444-1454.
41. Rossi J.J., June C.H., Kohn D.B. Genetic therapies against HIV. Nat. Biotechnol. 2007, 25:1444-1454.
42. Shimano R., Inubushi R., Oshima Y., Adachi A. Inhibition of HIV/SIV replication by dominant negative Gag mutants. Virus Genes 1999, 18:197-201.
43. Shimano R., Inubushi R., Oshima Y., Adachi A. Inhibition of HIV/SIV replication by dominant negative Gag mutants. Virus Genes 1999, 18:197-201.
44. Swanstrom R., Wills J.W. Synthesis, assembly, and processing of viral proteins. Retroviruses 1997, 263-334. Cold Spring Harbor Laboratory Press, New York. J.M. Coffin, S.H. Hughes, H.E. Varmus (Eds.).
45. Trono D., Feinberg M.B., Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989, 59:113-120.
46. Unwalla H., Li M., Kim J., Li H., Ehsani A., Alluin J., Rossi J. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat. Biotechnol. 2004, 22:1573-1578.
47. Unwalla H.J., Li M.J., Kim J.D., Li H.T., Ehsani A., Alluin J., Rossi J.J. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat. Biotechnol. 2004, 22:1573-1578.
48. Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11:636-646.
49. Vozzolo L., Loh B., Gane P.J., Tribak M., Zhou L., Anderson I., Nyakatura E., Jenner R.G., Selwood D., Fassati A. Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. J. Biol. Chem. 2010, 285:39314-39328.
50. Weaver J. Researchers knock down gene to stop HIV in its tracks. Nat. Med. 2010, 16:731.
51. Woffendin C., Ranga U., Yang Z., Xu L., Nabel G.J. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl Acad. Sci. USA 1996, 93:2889-2894.
52. Wyma D.J., Kotov A., Aiken C. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J. Virol. 2000, 74:9381-9387.